ALFA FinderBSE filing, NSE: AARTIPHARM. Summary written from the filing by ALFA Finder's alert engine.
Aarti Pharmalabs Ltd: key numbers
- Share price
- ₹929.10
- Market cap
- ₹8,425 Cr
- Revenue (annual)
- ₹1,819 Cr
- Net profit (annual)
- ₹174.7 Cr
- P/E (TTM)
- 32.8×Sector 43.0×
- Promoter holding
- 39.66%-3.20% QoQ
- FII holding
- 8.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Pharmalabs Ltd
All →Aarti Pharmalabs Earnings Call Transcript: Key Takeaways
Aarti Pharmalabs delivered record quarterly revenue driven by strong CDMO growth, though aggressive capex is temporarily elevating debt and working capital.
- Call
- Guides 45% growth
Aarti Pharmalabs Investor Presentation: Key Takeaways
Q2 FY27 standalone revenue INR 6,126Mn (+46.8% YoY), EBITDA INR 1,358Mn (22.2% margin), PAT INR 658Mn (+180% YoY). H1 revenue +44.7%. Xanthine capacity expansion and Atali capex drive growth.
Aarti Pharmalabs Management Change
Aarti Pharmalabs accepted CFO Piyush Lakhani's resignation, effective 30 October 2026, and appointed Vibha Thakker as CFO from 31 October 2026. The filing records a senior management change with no monetary amount.
Aarti Pharmalabs Q2 FY27 Results: Net Profit ₹71.5 Cr, Up 248.8% YoY
Aarti Pharmalabs Ltd reported revenue from operations of ₹610.5 Cr (+45.9% YoY) and net profit of ₹71.5 Cr (+248.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹71.5 Cr · +248.8% YoY
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
Other annual report announcements
All →Vineet Laboratories Annual Report
Vineet Laboratories filed its FY 2025-26 Annual Report, which marks its turnaround and recapitalisation year. The AGM is scheduled for 30 November 2026.
Indrayani Biotech Annual Report
Indrayani Biotech has filed its 34th Annual Report for FY2025-26, containing the AGM notice for 30 November 2026 by VC/OAVM. The chairman notes a Rights Issue was initiated in October 2026 to raise capital.
ESDS Software Solution Annual Report
ESDS Software Solution submitted its FY2025-26 Annual Report along with the AGM notice. The AGM is on 30 November 2026 via VC/OAVM, with remote e-voting.
The Orissa Minerals Development Company Annual Report
Orissa Minerals Development Company filed its FY 2025-26 Annual Report and 108th AGM notice, with the AGM set for 30 November 2026. The filing is a Regulation 34 intimation with no transaction or financial event.
Viksit Engineering Annual Report
Viksit Engineering filed its 44th Annual Report for FY 2025-26 with BSE. The report includes notice of the AGM on 30 November 2026.
Innovision Annual Report
Innovision Ltd filed its FY2025-26 Annual Report with the notice of its 20th AGM, scheduled for 5 December 2026 via VC/OAVM. The notice covers financial statements, a director re-appointment and a non-executive director regularisation.